Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) announced today that its shareholders have approved its combination with biotherapeutics firm Gelesis.
The deal was approved with a total of 24,835,281 votes in favor of the combination. A total of 25,643,831, or 74.3%, of CPSR’s issued and outstanding shares of common stock were present at yesterday’s special meeting. Although CPSR reached a high of $12.23 on January 10th, it quickly fell to a low of $6.06 today, and closed at $6.70.
The SPAC announced on Monday that all but $3.4 million have been removed from its trust via redemptions. A total of 27,260,179 shares were redeemed, including shares held by PIPE investors. Capstar noted that GCCU VI LLC and TOCU XXIX LLC redeemed 1,000,000 shares each, although each have also agreed to purchase 1,750,000 shares through the transaction’s PIPE. But, Capstar had already secured the deal’s completion in regards to its minimum cash condition by adding a backstop in late December.
Capstar also revised its agreement with Gelesis in early November in order to be re-struck on more investor-friendly terms. The changes slashed Gelesis’ proposed equity valuation by 25%, from $900 million to $675 million, in exchange for concessions on earnout shares and the sponsor’s promote.
The parties expect to close the deal shortly, and the combined company is expected to trade on the NYSE under the symbol “GLS”.
Capstar initially announced their combination on July 19. Boston-based Gelesis is advancing a series of therapies for weight management and chronic gut conditions with a consumer-facing approach.
ADVISORS
- Citi is serving as exclusive financial advisor to Gelesis
- Goodwin Procter LLP is serving as legal counsel to Gelesis.
- UBS Investment Bank is serving as exclusive financial and lead capital markets advisor to Capstar
- Kramer Levin Naftalis & Frankel LLP is serving as Capstar’s legal counsel.
- UBS Investment Bank and Citi are serving as private placement agents to Capstar with respect to the PIPE financing.
- Winston & Strawn LLP served as counsel to the placement agents.
- BTIG, LLC is also serving as a capital markets advisor to Capstar.
Evolution Global (NASDAQ:EVOXU) has filed for a $150 million SPAC to hunt for a domestic critical materials target just as the trade war heats up again. With this final S-1 filing of July, underwriter Cohen & Company put a pin in the new SPAC generation for the month. This brought July’s new SPAC filings to...
In July 2025, the SPAC market continued to show signs of resilience, even as shareholder activity moderated slightly from the previous month. Extension votes remained steady, with most proposals approved and many SPACs still early in their extension cycles. Although only one business combination received shareholder approval, four deals were ultimately completed during the month,...
At the SPAC of Dawn Just when the market thought it might have had a handle on this year’s sources of uncertainty, tariffs have once again returned to complicate the picture. The “reciprocal” tariffs announced and then postponed by the Trump administration are set to snap back in to force on August 7. For some...
HCM III Acquisition Corp. (NASDAQ:HCMAU) announced the pricing of its $220 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “HCMAU”, Friday, August 1, 2025. The new SPAC intends to focus on identifying businesses which provide disruptive technology or innovations within the financial services industry. HCM III is led...
Melar I (NASDAQ:MACI) has entered into a definitive agreement to combine with Italian e-commerce firm Everli at a pro forma enterprise value of $247 million. Everli delivers groceries to consumers via in-store shoppers at a wide range of retailers in the Italian market. The combined company is expected to trade on the Nasdaq under the...